Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

Autor: Garcia-Manero, Guillermo *, Platzbecker, Uwe, Santini, Valeria, Zeidan, Amer M., Fenaux, Pierre, Komrokji, Rami S., Shortt, Jake, Valcárcel, David, Jonášová, Anna, Dimicoli-Salazar, Sophie, Tiong, Ing Soo, Lin, Chien-Chin, Li, Jiahui, Zhang, Jennie, Giuseppi, Ana Carolina, Kreitz, Sandra, Pozharskaya, Veronika, Keeperman, Karen L., Rose, Shelonitda, Shetty, Jeevan K., Hayati, Sheida, Vodala, Sadanand, Degulys, Andrius, Paolini, Stefania, Cluzeau, Thomas, Porta, Matteo Della
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S145-S145
Databáze: ScienceDirect
Externí odkaz: